As of January 28, 2013 the US Small Business Innovation Research (SBIR) program is operating under a new set of rules drafted into the National Defense Authorization Act for the FY 2012. The redesigned platform will bring in smaller biopharma businesses and other technologies to both SBIR and Small Business Technology Transfer (STTR), according to a recent article on genengnews.com. One of the new rules raised the maximum amount of grand funding for an awardee business from $100,000 to $150,000 for Phase I, and from $750,000 to $1 million for Phase II. Additionally, Congress gave the programs their first budget increases since the end of FY 2008. The reauthorization of SBIR and STTR may help fund new startups and biopharma businesses, ultimately creating more jobs. To read the full article on genengnews.com, click here. To read SBA’s final rules on the Federal Register, click here. Need help in writing up your regulatory strategy or clinical plan for a grant submission? Contact us at firstname.lastname@example.org and we’d be happy to help.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.